AI screening for pulmonary hypertension in scleroderma
Part of Heart & circulation, Lungs & breathing, Skin clinical trials.
This study uses artificial intelligence to find better ways to screen for pulmonary arterial hypertension (a type of high blood pressure in the lungs) in people with systemic sclerosis (scleroderma). The goal is to catch the condition earlier so treatment can start sooner.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have been diagnosed with systemic sclerosis (scleroderma) by a doctor using standard criteria.
- You either have confirmed pulmonary arterial hypertension (PAH) or you have scleroderma without PAH (or certain other types of pulmonary hypertension limited to a small group).
- If you have PAH, it must have been confirmed by a right heart catheterization test with specific pressure measurements.
- You cannot have missing key information from your initial diagnosis (like test results or echocardiogram).
- You must be able to give informed consent to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses an AI tool to help doctors decide if you should be tested for pulmonary hypertension (high blood pressure in the lungs), which can be a complication of interstitial lung disease. If the tool suggests you might have it, you may get an echocardiogram (an ultrasound of the heart) and a right heart catheterization (a test to measure pressure in the heart) to find out for sure.
This study tests whether people with systemic sclerosis (scleroderma) and pulmonary arterial hypertension (PAH) can safely monitor their heart health at home using a smartphone or other internet-connected device. If you have PAH and are comfortable using technology, this trial may help make care more convenient.
This trial uses an artificial intelligence tool to look at results from tests used to evaluate pulmonary hypertension. It may help doctors make sense of your past test results, especially heart and lung evaluation results.
This study uses artificial intelligence to look for signs of pulmonary arterial hypertension (high blood pressure in the lungs) and related heart problems using heart ultrasound images and stethoscope recordings. Participating could help improve detection of this condition.
This trial is studying people who have both a connective tissue disease (like lupus or scleroderma) and pulmonary hypertension, which is high blood pressure in the lungs. By participating, doctors can learn more about how to better treat this combination.
This study is testing whether a new risk score can better predict outcomes for people who have both chronic lung disease and pulmonary hypertension (high blood pressure in the lungs). If you qualify, the researchers will follow your health over time to see how well the score works.
Hear when a new Pulmonary Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.